Sector Expert: Michael G. King, Jr.

JMP Securities

Image: Michael G. King, Jr.

Michael G. King Jr. is a managing director and senior biotechnology analyst at JMP Securities. King comes to JMP from Rodman & Renshaw LLC, where he was managing director and senior biotechnology analyst. He has more than 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sellside research survey, in addition to being named that publication's "Home Run Hitter" in 2000. King also served as senior vice president of corporate development and communication at ZIOPHARM Oncology (ZIOP:NASDAQ). Prior to joining ZIOPHARM, King was a managing director and senior biotechnology analyst at Wedbush Securities. He holds a bachelor's degree in finance from Baruch College.

Subscribe to
Streetwise Reports

Companies Commented On

  • Ardelyx Inc.
  • Calithera Biosciences Inc.
  • ChemoCentryx Inc.
  • Deciphera Pharmaceuticals Inc.
  • Fortress Biotech Inc.
  • Idera Pharmaceuticals
  • Kadmon Holdings Inc.
  • Karyopharm Therapeutics Inc.
  • Kura Oncology Inc.
  • Pieris Pharmaceuticals Inc.
  • Syndax Pharmaceuticals Inc.
  • ZZZZZFortress Biosciences Inc.


Recent Interviews

2018 Biotech Watchlist: 'No One Space Is Going to Dominate' (1/10/18)
2018 Biotech Watchlist

Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors.

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17 (7/13/17)
2017_watchlist

If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them.

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market (4/19/17)
2017_watchlist

The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.

Recent Quotes

"ASTX's shares still sell well below where we believe they could trade."

— Michael G. King, Jr., JMP Securities (9/16/13)
more >

"We are reiterating our Market Outperform rating on ASTX."

— Michael G. King, Jr., JMP Securities (8/19/13)
more >

"We maintain our Market Outperform rating on CYCC."

— Michael G. King, Jr., JMP Securities (8/14/13)
more >

"We maintain our Market Outperform rating on CYCC."

— Michael G. King, Jr., JMP Securities (8/14/13)
more >

"We continue to view ASTX as a highly attractive mid-cap play in the biotech space."

— Michael G. King, Jr., JMP Securities (8/1/13)
more >

"We maintain our Outperform rating for ASTX."

— Michael G. King, Jr., JMP Securities (7/8/13)
more >

"We are initiating coverage on CYCC with a Market Outperform rating."

— Michael G. King, Jr., JMP Securities (7/2/13)
more >

"We reiterate our Market Outperform rating on ASTX."

— Michael G. King, Jr., JMP Securities (4/30/13)
more >



Due to permission requirements, not all quotes are shown.